Why I’m Starting this Cholesterol Drug (For My Brain)
In a Nutshell
A doctor with two APOE4 genes (high Alzheimer's risk) is restarting ezetimibe—not for cholesterol/heart health, but for emerging evidence it disrupts the 14-3-3/hexokinase interaction driving protein misfolding in Alzheimer's, reducing amyloid/tau accumulation, boosting autophagy by 40%, and showing 8-fold lower dementia incidence in 4,361 patients vs. controls (per Aging Biology study with cell, worm, and retrospective human data). Despite caveats (no RCTs), its safety profile beats statins, prompting a personal low-dose trial (5 mg nightly) to test brain protection. Rapid tips: 5 mg lithium orotate, lysophosphatidylcholine DHA omega-3s (e.g., Ascentrate), and NR/NMN for NAD support, emphasizing genes aren't destiny.
These notes were generated by AI and may contain inaccuracies.
Shocking research changed my mind about this cholesterol-lowering medication, ezetimibe. It has nothing to do with cholesterol or heart health. I'm familiar with it from medical school and as a patient with one in 1 million high levels of cholesterol. Doctors have worried about my heart, but my heart is doing great and my arteries are clean. My concern is my brain. I'm at high genetic risk for Alzheimer's disease because I carry two copies of the risk gene APOE4.
Data show ezetimibe does something unexpected in the brain. It's like seeing ezetimibe as Bruce Wayne when it's also Brain Batman, fighting crime in the brain, not the heart. People die fast with dementia from infectious misfolded proteins. New study on ezetimibe and Alzheimer's—not statins, not PCSK9 inhibitors. This is not a cholesterol story. Signals like this are rare in medicine. Most interesting solutions come from looking where no one thought to look.
Road map: 1) Background on ezetimibe and Alzheimer's. 2) New study on ezetimibe and Alzheimer's with mechanistic and human data. 3) What I'm going to try next. 4) Rapid-fire tips for brain health and cognitive longevity. References in video description, newsletter, stay curious community.
Ezetimibe is a cholesterol-lowering medication that works in the gut. It selectively inhibits transporter NPC1L1 in the small intestines, responsible for absorbing dietary and biliary cholesterol. By blocking this, it reduces cholesterol delivered to the liver from intestines, prompting the liver to increase LDL receptors to pull more LDL out of circulation. Unlike statins, it doesn't inhibit cholesterol synthesis or downstream components like coenzyme Q10. It's gentler, safer, more benign.
Alzheimer's and neurodegenerative diseases driven by abnormal protein aggregation and misfolding—amyloid and tau in Alzheimer's, alpha-synuclein in Parkinson's. Proteins clump, neurons suffer and die, brain degenerates. Key interaction: scaffolding protein 14-3-3 and enzyme hexokinase (carbohydrate metabolism). 14-3-3 known from Creutzfeldt-Jakob disease (prions, infectious misfolded proteins, rapid dementia, 30% one-year survival).
14-3-3 plays role in Alzheimer's and Parkinson's. Normally, hexokinase sits on mitochondria. Pathologically, it detaches, binds 14-3-3, contributing to protein aggregation, cellular dysfunction, neuron death. 14-3-3/hexokinase binding is an early domino in Alzheimer's leading to amyloid, tau accumulation, neurons dying.
Published in Aging Biology. Researchers did hypothesis-naive screen for FDA-approved compounds interrupting 14-3-3/hexokinase interaction. Six drugs emerged, including ezetimibe. Pursued because it crosses blood-brain barrier, excellent safety profile, only cholesterol drug (not statins, PCSK9 inhibitors).
Not hunting cholesterol perks; asking what approved tools interrupt neurodegenerative interaction. Ezetimibe raised hand.
In human cell lines, ezetimibe significantly reduced amyloid accumulation (green) and tau accumulation (neurofibrillary tangles). Boosted autophagy by ~40% (cell's recycling/cleanup; mimics fasting in brain).
In C. elegans (worms) with glowing red neurotoxic amyloid, ezetimibe reduced accumulation.
Human cell lines and worms have limitations, but they analyzed clinical data: 4,361 ezetimibe patients vs. 945,000 age-matched controls. Alzheimer's and related dementias incidence 8-fold lower in ezetimibe group.
"Taken together, these findings suggest that ezetimibe confers a highly significant protection from Alzheimer's disease and related dementias in individuals with or without coronary disease."
Cholesterol-independent. Mechanisms warrant investigation, compelling for neuroprotection. Not a cholesterol story—Brain Batman.
Not definitive proof ezetimibe prevents Alzheimer's—no RCT. Limited to cell lines, in vitro, worms, retrospective human data. Probably never get ezetimibe monotherapy RCT for prevention. Mechanistically coherent, plausible. Effect size enormous: meaningful drops in amyloid/tau, 40% autophagy boost, 8-fold risk reduction (even with confounding, astronomical signal).
Ezetimibe benign vs. statins—no insulin resistance, diabetes, liver injury, muscle damage. I've considered/tried it (stopped due to diarrhea, common side effect in minority). Not dangerous, just unpleasant.
Track record: Highlight negatives of cholesterol therapy, give statins hard time, warn against reflexively lowering cholesterol/LDL/ApoB without physiology/context. No pharma ties—turned down six-figure sponsorships. Highlight compelling data challenging my bias.
Revisiting ezetimibe in year-long crossover experiment on metabolic markers, now for brain health. Obstacle: diarrhea. Previously tried 10 mg for weeks. Now: start 5 mg (half dose), 1 month to adapt, evening with food (reduces GI effects). Reduce magnesium from 400 mg to 200 mg (compounds diarrhea). If tolerate, maybe 5 mg twice daily. If not, stop. Risk-benefit tilts to benefit for brain, not CV.
Watching Obecetatib (new CCTP inhibitor, phase 3 done, Alzheimer's relevance—see related content).
- 5 mg lithium orotate daily (Pure Encapsulations, no affiliation—see video).
- 3 capsules Ascentrate Omega Max daily (lysophosphatidylcholine DHA, increases brain omega-3 in pre-clinical models; discount code stay curious 20% off—see content, especially APOE4 carriers).
- Over 40: Consider nicotinamide riboside or nicotinamide mononucleotide (boost NAD, declines with age, depleted in Alzheimer's—see content).
These tools can potentially prevent Alzheimer's even in high genetic risk (me: two APOE4, 10-15x risk). Genes not destiny. Paper reveals importance of looking where no one thought to look. Stay curious.
Keep Nick Norwitz in your library
Save the videos and channels worth coming back to, and find them again in one place.
